Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: U.S. trade barriers for OTCs

This article was originally published in The Tan Sheet

Executive Summary

U.S. trade barriers for OTCs: Process of obtaining FDA OTC drug approval for a new medicinal product in the U.S. is hampered by the requirement for a U.S. market history for the product, the European Commission 1997 Report on United States Barriers to Trade and Investment states. Also, the problem of admission of European suntan lotions to the U.S. market continues, the reports says, adding that "while the FDA did approve sunscreen products containing avobenzone in concentrations of up to 3%, final monographs covering this and other sunscreen products are still pending." BASF, Merck and Haarman & Reimer jointly and separately have been attempting to facilitate marketing of foreign OTC products in the U.S. ("The Tan Sheet" Jan. 13, pp. 8-9)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087429

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel